Pfizer NYSE: PFE
Name | Pfizer |
Ticker | PFE |
Exchange | NYSE |
Sector | Health Care |
Industry | Drug Manufacturers - Diversified |
Price | 36.50 |
52W Low/High | 28.49 / 42.56 |
Market cap | 203 B |
1Y Total Return |
-0.87%
Average |
1Y Volatility |
35.99%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Details
Ticker | PFE |
Name | Pfizer |
ISIN | US7170811035 |
CUSIP | 717081103 |
Exchange | NYSE |
Sector | Health Care |
Industry | Drug Manufacturers - Diversified |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) |
|
Share as of 1/20/21
Close Price | 36.50 |
52W Low/High | 28.49 / 42.56 |
Market cap | 203 B |
1Y Total Return |
-0.87%
Average |
1Y Volatility |
35.99%
Low Risk |
Beta | 0.34 |
PE (trailing) |
23.40
Average |
12M Dividends | 1.5 |
Last Dividend Date | 11/17/20 |
Dividend Yield | 4.11% |
Fin. Strength
Net Profit Margin | 17.9% |
Cash from Op. / Cur. Liabilities | 0.37 |
Diluted Earnings / Share | 1.56 |
ROE | 13.3% |
ROIC | 6.3% |
Price / Revenue | 4.2 |
Price / Book | 3.2 |
Price / CF | 16.4 |
Current Ratio | 1.4 |
Cur.Liabilities / Tot.Liabilities | 0.3 |
Financial Leverage | 0.97 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
48,648
|
53,039
|
53,373
|
52,471
|
53,244
|
47,922
|
|
Gross Profit |
38,852
|
42,353
|
41,944
|
41,288
|
40,724
|
38,983
|
|
R&D |
9,039
|
8,285
|
7,864
|
7,900
|
7,708
|
8,550
|
|
EBITDA |
13,586
|
24,485
|
20,072
|
18,354
|
12,821
|
16,147
|
|
Operating Income |
8,499
|
10,155
|
13,786
|
12,128
|
7,220
|
11,123
|
|
Net Income exc. Extra |
8,685
|
16,217
|
23,821
|
9,809
|
6,268
|
8,360
|
|
per Share | |||||||
Diluted avg Shares |
5,633
|
5,649
|
5,986
|
6,041
|
6,150
|
6,243
|
|
EPS exc. Extra |
1.56
|
2.88
|
3.96
|
1.62
|
1.01
|
1.33
|
|
Dividend |
1.50
|
1.42
|
1.34
|
1.26
|
1.18
|
1.10
|
|
Div. Yield (an.) |
4.16%
|
3.92%
|
3.04%
|
3.53%
|
3.48%
|
3.45%
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
178,983
|
170,446
|
167,838
|
172,151
|
178,430
|
170,867
|
|
Cash, Eq & Invt ShortTerm |
21,912
|
9,087
|
17,239
|
16,925
|
14,371
|
20,658
|
|
Total Current Assets |
47,739
|
33,459
|
41,583
|
40,291
|
38,501
|
45,001
|
|
Total Non-Current Assets |
131,244
|
136,987
|
126,255
|
131,860
|
139,929
|
125,866
|
|
Intangibles |
90,829
|
97,660
|
100,920
|
105,799
|
110,519
|
90,514
|
|
Total Liabilities |
113,487
|
105,051
|
96,174
|
111,041
|
114,829
|
103,743
|
|
Total Current Liabilities |
34,154
|
36,974
|
29,013
|
28,217
|
34,759
|
27,845
|
|
Long Term Debt |
79,333
|
68,077
|
67,161
|
82,824
|
80,070
|
75,898
|
|
Shareholder equity |
65,259
|
65,103
|
71,319
|
60,770
|
63,306
|
66,838
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
12,547
|
13,557
|
18,178
|
15,754
|
15,049
|
15,389
|
|
Depreciation |
5,115
|
6,267
|
6,317
|
6,244
|
5,632
|
5,064
|
|
Cash from Investing |
-15,434
|
-1,876
|
530
|
-3,068
|
-6,928
|
-2,270
|
|
Capex |
2,231
|
2,660
|
2,177
|
2,213
|
1,892
|
1,230
|
|
Cash from Financing |
1,698
|
-12,452
|
-17,777
|
-11,920
|
-8,209
|
-12,242
|
|
Stock Issued |
297
|
-13,432
|
-5,863
|
-4,271
|
-3,956
|
-5,896
|
|
Debt (LT) Issued |
10,250
|
9,696
|
-3,047
|
488
|
3,227
|
510
|
|
Free Cash Flow |
6,346
|
29,270
|
29,663
|
5,294
|
16,051
|
20,125
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
17.9%
|
30.6%
|
44.6%
|
18.7%
|
11.8%
|
17.4%
|
|
NCFO / Op.Income |
147.6%
|
133.5%
|
131.9%
|
129.9%
|
208.4%
|
138.4%
|
|
Current Ratio |
1.4
|
0.9
|
1.4
|
1.4
|
1.1
|
1.6
|
|
Financial Leverage D/E |
0.97
|
0.81
|
0.58
|
0.72
|
0.70
|
0.58
|
|
Return on Capital Avg |
6.3%
|
11.7%
|
18.2%
|
5.8%
|
4.7%
|
6.1%
|
|
Return on Shareholder Equity |
13.3%
|
23.8%
|
36.1%
|
15.8%
|
9.6%
|
11.5%
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available